

Table S3. PAI1 4G/5G distributions in independent breast cancer studies.

Genotype	Cases	Controls	OR (95%CI)	<i>p</i> -value
Blasiak and Smolarz (42)				
5G5G	29 (29.0)	37 (34.9)	1.00 (reference)	} 0.18
4G5G	40 (40.0)	48 (45.3)	1.06 (0.56-2.02)	
4G4G	31 (31.0)	21 (19.8)	1.88 (0.90-3.94)	
4G carriers			1.31 (0.73-2.35)	0.36
4G4G vs 5G carriers			1.80 (0.96-3.39)	0.065
Castello <i>et al.</i> (41) †				
5G5G	14 (13.4)	30 (28.9)	1.00 (reference)	} 0.025
4G5G	66 (63.5)	54 (51.9)	2.62 (1.26-5.43)	
4G4G	24 (23.1)	20 (19.2)	2.57 (1.08-6.13)	
4G carriers			2.56 (1.27-5.13)	0.007
4G4G vs 5G carriers			0.93 (0.39-2.19)	0.86
Castello <i>et al.</i> + Blasiak and Smolarz				
5G5G	43 (21.1)	67 (31.9)	1.00 (reference)	} 0.026
4G5G	106 (52.0)	102 (48.6)	1.62 (1.01-2.59)	
4G4G	55 (26.9)	41 (19.5)	2.09 (1.20-3.65)	
4G carriers			1.75 (1.12-2.72)	0.013
4G4G vs 5G carriers			1.52 (0.96-2.40)	0.073
Overall meta-analysis, including ABC-EPIC				
5G5G	563 (20.5)	453 (22.2)	1.00 (reference)	} 0.24
4G5G	1335 (48.7)	998 (48.9)	1.08 (0.93-1.25)	
4G4G	845 (30.8)	591 (28.9)	1.15 (0.98-1.35)	
4G carriers			1.10 (0.96-1.27)	0.17
4G4G vs 5G carriers			1.09 (0.96-1.24)	0.16

† Control data were provided by Dr. Amparrio Estelles (personal communication).